DE-INCYTE
Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming European Hematology Association (EHA) 2021 Virtual Congress, held virtually from June 9-17, 2021.
“We are pleased that data highlighting the strength of Incyte’s oncology portfolio and partner-sponsored programs will be presented at this year’s EHA Virtual Congress,” said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapeutics, Incyte. “In particular, data being presented at the congress – including the first presentation of data from our Phase 2 study of parsaclisib, our PI3kδ inhibitor, in autoimmune hemolytic anemia; an oral presentation on real-world data for ruxolitinib, our JAK1/JAK2 inhibitor; and an ePoster from our Phase 2 combination study of ruxolitinib and parsaclisib in patients with myelofibrosis – reinforce our commitment to finding solutions for patients with significant unmet medical needs.”
Key abstracts accepted by EHA include:
Oral Presentations
Ponatinib
OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)1 (Abstract #S153. Session: Response, Resistance and Treatment-Free Remission in CML.)
Ruxolitinib
Efficacy and Safety of Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Vs-Host Disease After Crossover in the Phase 3 REACH2 Study2 (Abstract #S236. Session: Stem cell transplantation – GvHD.)
Impact of Ruxolitinib on Survival of Patients with Myelofibrosis in Real World – Update of ERNEST (European Registry for Myeloproliferative Neoplasms) Study2 (Abstract #S158. Session: Population based studies in myeloid disorders.)
ePosters
Parsaclisib
Efficacy and Safety Results from an Open-Label Phase 2 Study of Parsaclisib for the Treatment of Autoimmune Hemolytic Anemia (AIHA) (Abstract #EP685. Session: Enzymopathies, Membranopathies and Other Anemias.)
Pharmacologic Inhibition of PI3kδ Reduces Autoantibody Formation and is Efficacious in a Preclinical Model of Autoimmune Hemolytic Anemia (Abstract #EP693. Session: Enzymopathies, Membranopathies and Other Anemias.)
FACIT-Fatigue Subscale Outcomes from an Ongoing Phase 2, Open-Label Study of the Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor Parsaclisib in Patients with Autoimmune Hemolytic Anemia (AIHA) (Abstract #EP706. Session: Enzymopathies, Membranopathies and Other Anemias.)
Ponatinib
French Real-Life Observational Study “TOPASE” Evaluating Safety and Efficacy of Ponatinib Confirms Induction of Deep Molecular Responses in 110 Resistant or Intolerant CML Patients (Abstract #EP679. Session: Chronic Myeloid Leukemia – Clinical.)
Ruxolitinib
An Epidemiological Study of the Cardiovascular Health and Thrombotic Risk Profiles of Patients with Myeloproliferative Neoplasms in Primary Care Across the United Kingdom2 (Abstract #EP1090. Session: Myeloproliferative Neoplasms – Clinical.)
Impact of Bone Marrow Fibrosis Grade on Response and Outcome in Patients with Primary Myelofibrosis Treated with Ruxolitinib: A Post-Hoc Analysis of the JUMP Study2 (Abstract #EP1092. Session: Myeloproliferative Neoplasms – Clinical.)
Healthcare Resource Utilization in Patients with Myeloproliferative Neoplasms: A Nationwide Matched Cohort Study2 (Abstract #EP1107. Session: Myeloproliferative Neoplasms – Clinical.)
Ruxolitinib-Parsaclisib Combination Studies
Add-On Parsaclisib (a PI3kδ inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study (Abstract #EP1075. Session: Myeloproliferative Neoplasms – Clinical.)
Tafasitamab
Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma3 (Abstract #EP553. Session: Aggressive Non-Hodgkin Lymphoma – Clinical.)
First-MIND: A Phase 1b, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed DLBCL3 (Abstract #EP496. Session: Aggressive Non-Hodgkin Lymphoma – Clinical.)
Lenalidomide-Induced Effects on Cell Surface Expression of CD19 and CD20 in DLBCL Cell Lines and Functional Impact on Antibody-Mediated Cytotoxicity3 (Abstract #EP879 . Session: Lymphoma Biology & Translational Research.)
In addition to the presentations noted above, more than 10 publications highlighting data from Incyte’s portfolio will be made available by EHA as publications. Notably, these publications include bioequivalence and bioavailability data for ruxolitinib’s once-daily extended release (XR) formulation – Bioequivalence of 50 mg Once-Daily Ruxolitinib Extended Release (XR) Tablets Compared to 25 mg Twice-Daily Ruxolitinib Immediate Release (IR) Tablets (Abstract #PB1706) and Relative Bioavailability and Dose Linearity of Five Strengths of Ruxolitinib Extended Release (XR) Tablets (Abstract #PB1717).
Full listings for oral presentations and ePoster sessions are available on the EHA website: https://library.ehaweb.org . Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at EHA will be available on demand for registered attendees beginning Friday, June 11, 2021, through Sunday, August 15, 2021.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com
and follow @Incyte
.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming EHA meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the FDA and other regulatory authorities outside of the United States; the Company’s dependence on its relationships with its collaboration partners; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020, and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.
________________
1
Takeda-sponsored abstract.
2
Novartis-sponsored abstract.
3
MorphoSys-sponsored abstract.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512006007/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BPP Signals Next Era of Growth, Unveiling New Global Parent Brand: Lyceum Education Group21.1.2026 10:03:00 CET | Press release
The creation of the new brand reflects the unique global reach of eleven leading education businesses across the UK, Europe, North America and Australia Today marks the launch of Lyceum Education Group, the new parent brand for 11 leading specialist education businesses across the UK, mainland Europe, Canada and Australia. Lyceum Education Group brings together leading specialist education providers, delivering a diverse portfolio of programmes to benefit learners and businesses globally. From its beginnings as BPP almost 50 years ago, to the creation of the Lyceum Education Group brand today, the move reflects the transition to become a leading, global education group, which will be the second largest post-secondary provider in the UK, and the fourth largest in Europe. Since its acquisition by TDR Capital in 2021, the Group has been acquiring new brands which encompass increased specialisms, diversifying its product ranges and entering new global markets. A clear focus for Lyceum Educ
Ageneau Group Chooses Generix WMS to Boost Growth21.1.2026 09:00:00 CET | Press release
Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, announces that Ageneau Group, a French transportation, logistics, and training company, has chosen Generix WMS and TradeXpress to modernize operational processes at its Angers (Trélazé) site, which has a covered area of 9,000 m² and state-of-the-art technological equipment, including automated guided vehicles (AGVs). “We needed a powerful and scalable tool that was in line with our values of cohesion, respect, and innovation. Generix was able to meet 100% of our specifications and support us with transparency and expertise,” said Arnaud Ageneau, co-director of processes, purchasing, and IT at the Ageneau Group. To support its growth and meet the changing needs of its customers, the Ageneau Group was looking for a solution capable of digitizing its operations, optimizing its flows, and providing advanced logistics to its teams. The group
International Zinc Association Partners With Pharmanova to Save Children in Zambia21.1.2026 09:00:00 CET | Press release
Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA), has announced a new partnership with leading Zambian pharmaceutical manufacturer Pharmanova Zambia Limited to expand access to life‑saving zinc treatments for children across Zambia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121178091/en/ Life-saving zinc-supplementation and oral rehydration salts kits are proactively distributed to Zambian children through the works of the International Zinc Association, Pharmanova, and the Zambian Ministries of Health and Education. The collaboration was formally celebrated during a ceremony in Lusaka with the Zambian Ministry of Health, Pharmanova Zambia Limited, and IZA represented by Environment Health & Sustainability Director Dr. Eric Van Genderen. IZA and Pharmanova have united in an effort to scale up treatment for childhood diarrhea using zinc, an essential micronutrient that stre
LatticeFlow AI Acquires AI Sonar, the Leading AI Discovery Platform, to Enable End-to-End, Secure AI Governance21.1.2026 08:22:00 CET | Press release
The acquisition establishes LatticeFlow AI as the industry’s first evidence-based AI governance solution, securely connecting on-prem AI discovery and evaluation with centralized governance operations LatticeFlow AI, a Swiss deep-tech company leading evidence-based AI governance, today announced during the World Economic Forum (WEF) the acquisition of Dublin-based AI Sonar Ltd, a wholly owned subsidiary of CloudSphere Ltd. AI Sonar’s leading edge AI discovery platform allows enterprises and ISVs to detect shadow AI. AI Sonar’s solution will continue to be offered under its brand name by LatticeFlow AI. With this acquisition, LatticeFlow AI will introduce the industry’s first end-to-end, evidence-based AI governance solution securely connecting on-prem AI discovery and evaluations with centralized SaaS governance operations, and covering GenAI, agentic and traditional AI systems. As part of the acquisition, LatticeFlow AI assumes full ownership of AI Sonar’s platform, intellectual prope
Ramboll and Acutro Form Strategic Alliance to Drive Smarter, More Sustainable Intelligent Buildings21.1.2026 08:13:00 CET | Press release
Ramboll, a global leader in engineering, architecture, and consultancy, has entered into a strategic, collaborative partnership with Acutro, specialists in building performance improvement and predictive, data-led maintenance. The partnership brings together Ramboll’s global engineering expertise and Acutro’s digital building intelligence capabilities, creating synergies that support innovation, learning, and value creation for both organisations and their clients. The collaboration enables Ramboll to explore advanced building intelligence tools that can strengthen its digital design capability, while providing Acutro with the opportunity to apply and evolve its platform across complex, real-world projects. Together, the partners will help clients make more informed decisions about performance, lifecycle value, and operational risk. The multi-year relationship provides Ramboll with access to Acutro’s cloud-native platform, creating opportunities to integrate real-time performance analy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom